Genprex Inc (NASDAQ:GNPX) announced an update Monday on the development of its non-small cell lung cancer drug, including positive study results.
In April, a study of its lead drug Oncoprex at the University of Texas was completed. The study examined the effects of the tumor suppressor gene TUSC2 found in Oncoprex in combination with immunotherapy treatment.
The study was part of a sponsored research agreement between the company and the UT MD Anderson Cancer Center, and research is still ongoing. Researchers are also looking into TUSC2 used in concert with small molecule drugs and immunostimulatory adjuvants, which activate the body’s immune system.
“Recent studies have shown that less than half of cancer patients qualify for approved immunotherapies based on the patient’s PD-1 or PD-L1 protein expression level,” Chief Operating Officer Julien Pham said. “Current immunotherapy treatment is only benefitting a small number of cancer patients. We are working to fill this gap by combining our lead drug candidate with approved immunotherapies to give patients more treatment options.”
Genprex is a clinical stage gene therapy company based in Austin, Texas focused on developing cancer treatments.
Its stock slipped 3.2% to $1.20 a share in morning trading.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel